$GYRE News
Last published 6d ago
- 6d agoGYREGYRE THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 6d agoGYREGyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesGlobeNewswireQ3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre
- 6d agoGYREGyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesGlobeNewswireQ3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 ...
- 1mo agoGYREMorgan Stanley 24th Annual Global Healthcare Conference - GYRE THERAPEUTICS INCEarnings Call TranscriptsGreat. Welcome to the annual Global Morgan Stanley Healthcare Conference. Appreciate your time today. We have the pleasure of hosting Jeyer Therapeutics for the first time here at our conference. We, just before we get s
- 1mo agoGYREGyre Therapeutics 24th Annual Global Healthcare Conference - GYRE THERAPEUTICS INCEarnings Call TranscriptsGreat. Welcome to the annual Global Morgan Stanley Healthcare Conference. Appreciate your time today. We have the pleasure of hosting Jeyer Therapeutics for the first time here at our conference. We, just before we get s
- 2mo agoGYREGyre Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United
- 3mo agoGYREGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewswireQ2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May
- 3mo agoGYREGyre Therapeutics Appoints Three New Members to its Board of DirectorsGlobeNewswireSAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with
- 6mo agoGYREGyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis TreatmentGlobeNewswireSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United
- 6mo agoGYREGyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateGlobeNewswireQ1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in
- 6mo agoGYREGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyGlobeNewswirePost-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.China
- 8mo agoGYREGyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and PipelineGlobeNewswireAcquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of degraders, targeting inflammatory diseases and cancers.Access
- 10mo agoGYREGyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA MeetingGlobeNewswireGyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to
- 1y agoGYREGyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewswireNet income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to
- 1y agoGYREGyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of PneumoconiosisGlobeNewswireSAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by
- 1y agoGYREGyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025GlobeNewswireSAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems
- 1y agoGYREGyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems
- 1y agoGYREGyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of DirectorsGlobeNewswireSAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems
- 1y agoGYREGyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership UpdateGlobeNewswireNet income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman,
- 1y agoGYREGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaGlobeNewswireSAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems
- 1y agoGYREGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems
- 1y agoGYREGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockGlobeNewswireSAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously
- 1y agoGYREGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockGlobeNewswireSAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an
- 1y agoGYREGyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in ChinaGlobeNewswireAchieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for
- 1y agoGYREGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireQ1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently
- 1y agoGYREGyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary ComplicationsGlobeNewswireSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical
- 1y agoGYREGyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational HepatologyGlobeNewswireSAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today
- 1y agoGYREGyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireData from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of
- 1y agoGYREGyre Therapeutics Announces the Appointment of Ping Zhang to Board of DirectorsGlobeNewswireSAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 1y agoGYREGyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateGlobeNewswireLast patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025
- 2y agoGYREGyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisGlobeNewswireSAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of
- 2y agoGYREGyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceGlobeNewswireSAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoGYREGyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoBYRNCIACOOTDTIL+9Sidoti Events, LLC's Virtual August Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 13, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
- 2y agoGYREGyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateGlobeNewswireReceived NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of
- 2y agoGYREGyre Therapeutics to Present at Sidoti Virtual Investor ConferenceGlobeNewswireSAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoBDTXGYREGyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsGlobeNewswireSAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoGYREGyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaGlobeNewswireSAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoGYREGyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyGlobeNewswireSAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ
- 2y agoGYREGyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionGlobeNewswireSAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ
- 2y agoGYREGyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesGlobeNewswireSAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ
- 2y agoGYREGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of
- 2y agoGYREGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswireData readout from Phase 3 clinical trial in the People's Republic of China ("PRC") evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating
- 2y agoGYREGyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumGlobeNewswireSAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today
- 2y agoCBIOGYRETotus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingPR NewswireTotus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that...
- 2y agoGYREGyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver MeetingGlobeNewswireSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver diseases, today